Latest & greatest articles for carvedilol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carvedilol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on carvedilol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for carvedilol

21. Reimbursement claims analysis of outcomes with carvedilol and metoprolol

Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Luzier A B, Antell L A, Chang L L, Xuan J W, Roth D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of carvedilol and metoprolol, two beta-blockers, for the treatment of heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with HF. The inclusion criteria specified patients aged between 18 and 64 years with the following: two in- or outpatient medical claims with HF (International

2002 NHS Economic Evaluation Database.

22. Effect of carvedilol on survival in severe chronic heart failure. Full Text available with Trip Pro

Effect of carvedilol on survival in severe chronic heart failure. Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure.We evaluated 2289 patients who had symptoms of heart failure at rest or on minimal exertion, who were clinically euvolemic, and who had an ejection fraction of less than 25 percent. In a double-blind fashion, we randomly assigned 1133 patients to placebo (...) and 1156 patients to treatment with carvedilol for a mean period of 10.4 months, during which standard therapy for heart failure was continued. Patients who required intensive care, had marked fluid retention, or were receiving intravenous vasodilators or positive inotropic drugs were excluded.There were 190 deaths in the placebo group and 130 deaths in the carvedilol group. This difference reflected a 35 percent decrease in the risk of death with carvedilol (95 percent confidence interval, 19 to 48

2001 NEJM Controlled trial quality: predicted high

23. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. (Abstract)

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure.In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV (...) and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients.As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent

2001 NEJM Controlled trial quality: uncertain

24. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. (Abstract)

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The beneficial effects of beta-blockers on long-term outcome after acute myocardial infarction were shown before the introduction of thrombolysis and angiotensin-converting-enzyme (ACE) inhibitors. Generally, the patients recruited to these trials were at low risk: few had heart failure, and none had measurements of left-ventricular function taken. We (...) investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice.In a multicentre, randomised, placebo-controlled trial, 1959 patients with a proven acute myocardial infarction and a left-ventricular ejection fraction of carvedilol (n=975) or placebo (n=984). Study medication was progressively increased to a maximum of 25 mg

2001 Lancet Controlled trial quality: predicted high

25. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs Fowler M B, Vera-Llonch N, Oster G, Bristow M R, Cohn J N, Colucci W S, Gilbert E M, Lukas M A, Lacey M J, Richner R, Young S T, Packer M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A strategy of adding carvedilol to current treatment regimes for patients with heart failure was evaluated. Current treatment regimes included diuretics, digoxin and angiotensin-converting enzyme (ACE) inhibitors. Patients tolerating

2001 NHS Economic Evaluation Database.

26. Cost effectiveness of carvedilol for heart failure

Cost effectiveness of carvedilol for heart failure Cost effectiveness of carvedilol for heart failure Cost effectiveness of carvedilol for heart failure Delea T E, Vera-Llonch M, Richner R E, Fowler M B, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Use of carvedilol plus conventional therapy (digoxin, diuretics, and angiotensin-converting enzyme inhibitors) in the treatment of chronic heart failure (CHF). Type of intervention Secondary prevention and treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical patients with CHF. Setting Hospital. The economic study was carried out in the USA. Dates to which data relate Effectiveness data were obtained from studies published in 1991

1999 NHS Economic Evaluation Database.

27. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. (Abstract)

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. In patients with heart failure, beta-blocker therapy improves left-ventricular function after 3-6 months of treatment, but effects of such treatment on symptoms and exercise performance are inconsistent, and the longer-term effects on death and other serious clinical events remain uncertain. We have (...) investigated these issues in a double-blind, placebo-controlled, randomised trial of the beta-adrenergic blocker carvedilol (which also has alpha 1-blocking properties).415 patients with chronic stable heart failure were randomly assigned treatment with carvedilol (207) or matching placebo (208). At baseline, 6 months, and 12 months, we measured left-ventricular ejection fraction, left-ventricular dimensions, treadmill exercise duration, 6 min walk distance, New York Heart Association (NYHA) class

1997 Lancet Controlled trial quality: predicted high

28. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. (Abstract)

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these drugs on survival has not been determined.We enrolled 1094 patients with chronic heart failure in a double-blind, placebo-controlled, stratified program, in which patients were assigned to one of the four (...) treatment protocols on the basis of their exercise capacity. Within each of the four protocols patients with mild, moderate, or severe heart failure with left ventricular ejection fractions < or = 0.35 were randomly assigned to receive either placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor remained constant. Patient were observed for the occurrence death or hospitalization for cardiovascular reasons

1996 NEJM Controlled trial quality: predicted high